Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Clinical trial NCT06788938 · RECRUITING
Trial details
- NCT number
- NCT06788938
- Sponsor
- Jonsson Comprehensive Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-21
- Primary completion
- 2028-04-24
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.